Panion & Bf BiotechTPE:1760 -2.30%74 FCF Margin % is 15.53% as of Dec. 2025, which is 112% above its 10-year median of 7.32. GuruFocus rates TPE:1760 with a GF Score™ of 74/100 and a GF Value™ of NT$95.99 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Panion & Bf Biotech ranks better than 80.81% on this metric.
The historical rank and industry rank for Panion & Bf Biotech's FCF Margin % or its related term are showing as below:
TPE:1760'
s FCF Margin % Range Over the Past 10 Years
Min: -7.38 Med: 7.32 Max: 12.16
Current: 7.33
During the past 13 years, the highest FCF Margin % of Panion & Bf Biotech was 12.16%. The lowest was -7.38%. And the median was 7.32%.
TPE:1760's FCF Margin % is ranked better than 80.81% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs TPE:1760: 7.33
Panion & Bf Biotech FCF Margin % Related Terms
Panion & Bf Biotech FCF Margin % Historical Data
* Premium members only.
The historical data trend for Panion & Bf Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1760 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Panion & Bf Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panion & Bf Biotech FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Panion & Bf Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Panion & Bf Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panion & Bf Biotech (TPE:1760) has a FCF Margin % of 15.53% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Panion & Bf Biotech and its competitors. This is 112% above median its historical median of 7.32. According to the industry distribution chart, Panion & Bf Biotech ranks #184 out of 959 companies in the Biotechnology industry, placing it in the top 19.2%.
Is Panion & Bf Biotech's FCF Margin % too high?
Panion & Bf Biotech's current FCF Margin % of 15.53% is 112% above median its 10-year median of 7.32. Based on the distribution chart, Panion & Bf Biotech ranks #184 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Panion & Bf Biotech has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Panion & Bf Biotech ranks #184 out of 959 companies for FCF Margin %. This places Panion & Bf Biotech in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Panion & Bf Biotech and its competitors. Panion & Bf Biotech's current FCF Margin % is 15.53%, which is 112% above median its own 10-year median of 7.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$95.99, compared to a current price of NT$59.60 — trading 37.9% below its estimated fair value. The current FCF Margin % is 15.53%, which is 112% above median its 10-year median of 7.32. Panion & Bf Biotech's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current FCF Margin % is 15.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?
Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued.
The current stock price of NT$59.60 is trading 37.9% below its estimated GF Value™ of NT$95.99.
GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1760:
FCF Margin %: 15.53% (112% above median its 10-year median of 7.32)
GF Value™: NT$95.99 vs. price of NT$59.60 (37.9% below fair value)
No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
74GF Score
Get the complete analysis for TPE:1760
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1760 has been successfully added to your 
